- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03203954
Testing the Neuroscience of Guided Learning in Depression
Neural Substrates of Reinforcement Learning and Its Training in Major Depression
Study Overview
Status
Conditions
Detailed Description
Major depressive disorder ranks among the most significant causes of mortality and disability in the world. Recent data from the investigators and others highlight that impairments in reward and loss learning are central to depression, have distinct neural substrates, and improve with successful treatment. Together, these findings suggest an urgent need to delineate the relationships among neural and behavioral learning impairments and depression. Equally important, these insights suggest new targets for treatment such that manipulating the neural and behavioral substrates of learning may facilitate symptom change in depression.
To address these issues, the investigators use functional neuroimaging and a computational psychiatry framework to i) systematically characterize the neural and behavioral substrates that attend reward- and loss- learning in depression and ii) assess the degree to which learning in depression responds to two behavioral methods that target learning in different ways. The investigators test the broad hypotheses that i) that depression may be characterized by distinct neural and behavioral disruptions of learning, and ii) these disruptions and associated symptoms may be ameliorated through different methods of guiding learning. Recent advances in computational psychiatry provide a mechanism-based framework within which to understand the nature and trajectory of potential learning impairments in depression and suggest new ways that disrupted learning and associated symptoms may be improved in depression
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Virginia
-
Roanoke, Virginia, United States, 24016
- Virginia Tech Carilion Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- males and females of all ethnicities
- meet diagnostic criteria for major depression or non-depressed control (assessed by study staff)
- ages 18-55
- fluent in English
- able to see computer display clearly
- able to provide informed consent
- able to follow verbal or written instructions
- for participants who are referred by a clinician, a letter from that clinician indicating that participation in the study does not constitute an elevated medical or behavioral risk to the participant will be requested.
Exclusion Criteria:
- current pregnancy or menopause
- claustrophobia
- MRI contraindications
- psychotic or bipolar disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: No Training
Guided learning, standard learning: Repeat administration of standard behavioral learning task
|
Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
|
Experimental: Instructed Statistics
Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
|
Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
|
Experimental: Not Instructed Statistics
Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
|
Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Task performance
Time Frame: approximately 6 weeks (pre- post- learning task changes and interim time points)
|
behavioral measures of learning task performance including accuracy, learning rate
|
approximately 6 weeks (pre- post- learning task changes and interim time points)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neuroimaging measures
Time Frame: approximately 6 weeks (pre- post- learning task changes and interim time points)
|
functional MRI during learning task performance
|
approximately 6 weeks (pre- post- learning task changes and interim time points)
|
Symptoms
Time Frame: approximately 6 weeks (pre- post- learning task changes and interim time points)
|
self-report questionnaires and clinician-obtained symptom measures
|
approximately 6 weeks (pre- post- learning task changes and interim time points)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDDLEARNING
- R01MH106756 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Standard Learning
-
University of BernCompletedUltrasonography | Educational TechniquesSwitzerland
-
University of Colorado, DenverCompletedAnxiety DisordersUnited States
-
Center Eugene MarquisRecruiting
-
St. Justine's HospitalCompleted
-
Herning HospitalCompletedRehabilitationDenmark
-
Aarhus University HospitalNovo Nordisk A/S; TrygFonden, Denmark; Aalborg University Hospital; Horsens Hospital and other collaboratorsActive, not recruitingRheumatoid Arthritis | Self Efficacy | Patient InvolvementDenmark
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
Columbia UniversityChildren's Learning Centers of Fairfield CountyCompletedBehavior Problem | Emotional Disturbances | Family Conflict | Development Delay | Relation, Mother-ChildUnited States
-
KU LeuvenKom Op Tegen KankerEnrolling by invitationColorectal CancerBelgium